Skip to Content

Startup: Designer Life

Startup Codon Devices is creating entirely synthetic cells, proteins, and microorganisms. Someday they could be used to produce drugs or clean up pollution.
September 1, 2005

Last year, some 250 engineers, computer scientists, and biologists gathered at MIT for the first conference in a new field called synthetic biology. Their common goal: designing and building from scratch artificial biological systems such as cells or microorganisms that can do anything from producing drugs to cleaning up pollution. But conference goers agreed that to achieve such a goal, they will need better tools for synthesizing the long stretches of DNA required to build the synthetic organisms’ genomes.

Just a few months after the conference, some of the researchers founded a synthetic-biology startup called Codon Devices to provide those tools. With $13 million in venture capital funding, Codon is developing high-speed, low-cost DNA synthesis technology that could make synthetic biology a reality. By the end of this year, the company hopes to begin collaborating with academic researchers, helping them with DNA design and fabrication and delivering to them engineered DNA, proteins, or cells as products.

Codon’s technology could enable improved protein-based therapeutics and vaccines. Since synthetic biologists engineer genomes from scratch, instead of modifying naturally occurring ones, they should be able to create proteins and cells with novel and complex capabilities. Synthetic biologists say they want to design and build genomes in the same way that electrical engineers make integrated circuits. “They’ve been doing large-scale integrated circuits since I was a kid. Now we’re trying to do large-scale integrated biological circuits,” says Harvard Medical School geneticist George Church, Codon’s cofounder and chief scientific officer.

Although synthetic biologists can design DNA sequences for engineered organisms, they lack affordable tools that can quickly, automatically, and accurately turn those sequences into DNA molecules. With current methods, for instance, it can take many years, $10 million, and lots of manual handling and reagents to make a bacterial genome that is five million DNA letters long. And the process is prone to error: each letter of the final molecule has a 1 percent chance of being incorrect.

Within the next two years, Codon’s technology should reduce the time and cost of synthesizing DNA to about one-hundredth to one-thousandth of their current rates. That will enable the fabrication of longer stretches of DNA, says the company. And Codon aims to reduce the error rate to between one-thousandth and one-ten-thousandth of the current rate.

Codon researchers use the basic approach of conventional DNA synthesis but have streamlined the process to cut down on the number of steps, the volume of reagents, and the manual transferring of reagents between containers–all of which allows for more automation. Key to the system is the use of a gene chip on which thousands of small fragments of the desired DNA sequence are synthesized in parallel in one step. The company’s DNA-design software determines how to parcel out the sequence so that once the fragments are synthesized they can be pieced together with minimal labor.

The startup will face technical hurdles. For one, it may be difficult for Codon’s gene chip-based synthesis technology to handle certain types of sequences, such as very repetitive ones, says John Mulligan, CEO of Blue Heron Biotechnology, a Bothell, WA, gene synthesis company that is also looking to use gene chips.

And there are business challenges as well. Codon is the first startup to try to commercialize synthetic biology. “It may take a little while to shake out the business models,” says Mulligan. But the startup is right to focus on selling its DNA design capabilities, rather than just its DNA synthesis services, he says. “That’s where the high value is.” – By Corie Lok

Keep Reading

Most Popular

light and shadow on floor
light and shadow on floor

How Facebook and Google fund global misinformation

The tech giants are paying millions of dollars to the operators of clickbait pages, bankrolling the deterioration of information ecosystems around the world.

This new startup has built a record-breaking 256-qubit quantum computer

QuEra Computing, launched by physicists at Harvard and MIT, is trying a different quantum approach to tackle impossibly hard computational tasks.

wet market selling fish
wet market selling fish

This scientist now believes covid started in Wuhan’s wet market. Here’s why.

How a veteran virologist found fresh evidence to back up the theory that covid jumped from animals to humans in a notorious Chinese market—rather than emerged from a lab leak.

protein structures
protein structures

DeepMind says it will release the structure of every protein known to science

The company has already used its protein-folding AI, AlphaFold, to generate structures for the human proteome, as well as yeast, fruit flies, mice, and more.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at with a list of newsletters you’d like to receive.